Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2026)

Adaptive Biotechnologies has reported Total Current Liabilities for 9 years, with the latest figure at $87.0 million in Q1 2026.

• Quarterly Total Current Liabilities fell 0.91% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.0 million (down 0.91% YoY) and the FY2025 annual result came in at $89.9 million, down 8.3% from the prior year.
• Total Current Liabilities eased to $87.0 million in Q1 2026 per ADPT's latest filing, from $89.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $115.1 million in Q1 2022 and troughed at $83.0 million in Q1 2024.
• A 5-year average of $94.4 million and a median of $90.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities retreated 21.7% in 2023, then rose 11.4% in 2024.
• Over 5 years, Total Current Liabilities stood at $109.8 million in 2022, then fell by 19.83% to $88.0 million in 2023, then increased by 11.4% to $98.1 million in 2024, then decreased by 8.3% to $89.9 million in 2025, then slipped by 3.23% to $87.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $87.0 million, $89.9 million, and $83.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.